Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Total Liabilities (2019 - 2025)

Harmony Biosciences Holdings' Total Liabilities history spans 7 years, with the latest figure at $401.4 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 18.05% year-over-year to $401.4 million; the TTM value through Dec 2025 reached $401.4 million, up 18.05%, while the annual FY2025 figure was $401.4 million, 18.05% up from the prior year.
  • Total Liabilities for Q4 2025 was $401.4 million at Harmony Biosciences Holdings, up from $373.1 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $401.4 million in Q4 2025 and bottomed at $229.4 million in Q1 2021.
  • The 5-year median for Total Liabilities is $298.0 million (2022), against an average of $299.1 million.
  • The largest annual shift saw Total Liabilities plummeted 51.77% in 2021 before it grew 27.09% in 2023.
  • A 5-year view of Total Liabilities shows it stood at $246.9 million in 2021, then rose by 9.76% to $271.0 million in 2022, then increased by 27.09% to $344.5 million in 2023, then fell by 1.28% to $340.0 million in 2024, then grew by 18.05% to $401.4 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Total Liabilities are $401.4 million (Q4 2025), $373.1 million (Q3 2025), and $334.9 million (Q2 2025).